Regulatory P pharmaphorum
Bayer bags FDA green light for stroke drug Sunharbo
Bayer bags FDA green light for stroke drug Sunharbo Phil.Taylor Tue, 10/11/2026 - 09:36
Regulatory headlines from across biotech and life sciences, gathered from the industry press and linked straight to the publisher. Every story links straight to its publisher.
Regulatory P pharmaphorum
Bayer bags FDA green light for stroke drug Sunharbo Phil.Taylor Tue, 10/11/2026 - 09:36
Regulatory F FDA Law Blog
Regulatory
Drug Discovery and Development
Compass Pathways completed its NDA for COMP360 psilocybin in treatment-resistant depression as Usona, Definium and other psychedelic developers advance. The post Psychedelic pioneer Compass files for FDA approval as rivals close in appeared first on Drug Discovery and Development…
Regulatory
BioCentury
BIOCENTURY | POLITICS, POLICY & LAWOVERTON CONFIRMATION UNLIKELY, BRENNER UNDER CONSIDERATION AS ACTING FDA COMMISSIONERDeparture of Susie Wiles as chief of staff removes pharma’s White House point of contact
Regulatory
Drug Discovery and Development
The FDA is requiring all GLP-1 drug labels to carry a NAION warning, though trial and observational data on the eye-stroke risk are mixed. The post FDA’s GLP-1 vision warning rests on mixed evidence appeared first on Drug Discovery and Development.
Regulatory
BioPharma Dive
Sunharbo’s U.S. approval is the first for a “Factor XIa” inhibitor, an anticipated class of medicines seen as a possible step forward in stroke prevention.
Regulatory
STAT Biotech
Bayer's drug is the first in a novel class of medications designed to prevent blood clots without increasing risk of bleeding.
Regulatory
FDA Press Announcements
FDA today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient isc…
Regulatory
MedTech Dive
The FDA had uncertainty about the degree of clinical benefit for Novocure’s treatment of brain metastases, the company said.
Regulatory
STAT Biotech
The FDA on Monday warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition that's sometimes referred to as an "eye stroke."
Regulatory
MedTech Dive
The agency is inviting public comment on a new discussion paper as it prepares to shape policy covering robotic medical devices with autonomous or remote teleoperation functions.
Regulatory P pharmaphorum
MHRA grants Innovation Passports to three novel drugs Phil.Taylor Mon, 09/11/2026 - 12:55
Regulatory A Applied Clinical Trials
In today’s ACT Brief, we examine why APAC inspection findings mirror those in the US and Europe, how key risk indicators should be read together, and how FDA granted accelerated approval to a subcutaneous antibody therapy for recurrent head and neck cancer.
Regulatory
Pharmaceutical Technology
China's NMPA has granted marketing authorisation for Bio-Thera Solutions’ BAT2506 to treat ankylosing spondylitis and rheumatoid arthritis.
Regulatory F FDA Law Blog
By Steven J. Gonzalez & Jennifer D. Newberger —
Regulatory
MedCity News
Accelerated FDA approval of Johnson & Johnson’s Rybrevant Faspro covers advanced cases of head and neck cancer. The bispecific antibody was initially approved for treating certain lung cancers. The post Bispecific J&J Drug Wins Speedy FDA Approval for Treating Head &…
Regulatory P Pharmaceutical Executive
Hims & Hers partners with Eli Lilly to sell Zepbound and Foundayo directly on its platform, Novo Nordisk terminates its research collaboration with Korro Bio, and the FDA grants accelerated approval to Johnson & Johnson’s Rybrevant Faspro in head and neck cancer.
Regulatory B BioPharm International
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio T…
Regulatory B BioPharm International
Johnson & Johnson's amivantamab (Rybrevant Faspro) won accelerated FDA approval for pretreated recurrent head and neck cancer.
Regulatory
PharmaVoice
American voters turned their noses up at MAHA-aligned candidates this week; Inovio won a breakthrough nod for a DNA-based therapy.
Regulatory
BioSpace
After the FDA delayed a decision for Agios Pharmaceuticals’ sickle cell disease candidate, the biopharma is letting go of more than 35% of its R&D employees.
Regulatory P Pharmaceutical Executive
Accelerated approval of subcutaneous Rybrevant Faspro (amivantamab) based on a 42% response rate in 102 patients; a phase 3 confirmatory trial is under way.
Regulatory A Applied Clinical Trials
In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, explains how FDA inspection findings at APAC sites compare with those in the US and Europe, and why the common issues, such as informed consent versioning, are not unique to th…
Regulatory
Pharmaceutical Technology
The accelerated approval marks the first indication beyond lung cancer for J&J’s bispecific antibody.
Regulatory
Pharmaceutical Technology
Through its PPIE initiative, the MHRA plans to consider a diverse range of patient and public opinions when making regulatory decisions.
Regulatory
Pharmaceutical Technology
Alfasigma has received the EC's expanded approval for Jyseleca to treat adult patients living with active axial spondyloarthritis (axSpA).
Regulatory P pharmaphorum
J&J's Rybrevant Faspro moves beyond lung cancer with FDA nod Phil.Taylor Fri, 06/11/2026 - 09:41
Regulatory S Science News
Critics say ballot measure’s narrow language will funnel taxpayer money to a single, billionaire-backed nonprofit
Regulatory
Nature Reviews Drug Discovery
Regulatory
FDA Press Announcements
The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platin…
Regulatory B BioPharm International
FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
Regulatory
MHRA
New plan will broaden participation and make clearer how patient experience informs regulatory decisions, safety and innovation
Regulatory B BioPharm International
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Regulatory
BioCentury
BIOCENTURY | DATA BYTEFDA APPROVES FIRST DNA PLASMID IMMUNOTHERAPY; NME TALLY REACHES 47Two October approvals push 2026 total past full-year 2025, with two months remaining
Regulatory
Clinical Trials Arena
The MHRA's guidance details its context-based, risk-proportionate approach to assessing non-clinical safety data outside of OECD standards. The post MHRA debuts guidance shifting rules around non-clinical safety data appeared first on Clinical Trials Arena.
Regulatory
Drug Delivery Business
Insulet’s (Nasdaq: PODD) third quarter outpaced its own expectations and those of Wall Street, boosted by international sales of its Omnipod 5 tubeless insulin pump. Total revenue reached $842.0 million, for a 19.6% gain over the prior year, topping the company’s previous guidanc…
Regulatory
MHRA
MHRA issues new guidance on its approach to clinical trial applications that rely on non-clinical safety data generated outside the OECD Mutual Acceptance of Data system.
Regulatory B BioPharm International
Biora will test oral adalimumab via its BioJet capsule vs injection in healthy volunteers, with dosing from December 2026 and data in early 2027.
Regulatory
PharmaVoice
Investors and payers sometimes balk at drugs approved on an accelerated pathway. Here’s how pharma can de-risk these medications while they’re still in development.
Regulatory
Pharmaceutical Technology
The FDA has accepted a BLA under its accelerated approval pathway from uniQure for ifezuntirgene inilparvovec to treat Huntington’s disease.